Dexlansoprazole(R-Lansoprazole)

Molecular Weight (MW)	369.36
Formula	C16H14F3N3O2S
CAS No.	138530-94-6
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 74 mg/mL (200.3 mM)
Water:<1 mg/mL
Ethanol: 74 mg/mL (200.3 mM)
Other info	Chemical Name: (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole InChi Key: MJIHNNLFOKEZEW-RUZDIDTESA-N InChi Code: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1 SMILES Code: O=[S@@](C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C
Synonyms	T-168390; TAK-390MR; TAK-390; T168390; TAK390; T 168390; TAK 390; Dexlansoprazole; Dexilant; Kapidex; TAK 390MR; TAK390MR

Molecular Weight (MW)

369.36

Formula

C16H14F3N3O2S

CAS No.

138530-94-6

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 74 mg/mL (200.3 mM)

Water:<1 mg/mL

Ethanol: 74 mg/mL (200.3 mM)

Other info

Chemical Name: (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole

InChi Key: MJIHNNLFOKEZEW-RUZDIDTESA-N

InChi Code: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

SMILES Code: O=[S@@](C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C

Synonyms

T-168390; TAK-390MR; TAK-390; T168390; TAK390; T 168390; TAK 390; Dexlansoprazole; Dexilant; Kapidex; TAK 390MR; TAK390MR

In Vitro	In vitro activity: Dexlansoprazole, constitutes>80% of circulating drug after oral administration of lansoprazole, provides lower clearance and 5-fold greater systemic exposure than the S-enantiomer following oral administration of lansoprazole. Dexlansoprazole MR is a modified release formulation of dexlansoprazole, which employs a novel Dual Delayed Release (DDR) technology that delivers the drug in two discrete phases of release, thereby inhibiting newly activated proton pumps that turn over following initial PPI inactivation of H+,K+-ATPase. Dexlansoprazole MR maintains plasma drug concentrations above the threshold level longer than lansoprazole at all doses, resulting in an optimized drug exposure-intragastric pH relationship. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H+K+-ATPase proton pump in the gastric parietal cell, inhibition of this cell membrane enzyme ultimately blocks the final step in acid production.
In Vivo
Animal model
Formulation & Dosage
References	Aliment Pharmacol Ther. 2009 May 1;29(9):928-37; Clin Ther. 2010 Aug;32(9):1578-96.

In Vitro

In vitro activity: Dexlansoprazole, constitutes>80% of circulating drug after oral administration of lansoprazole, provides lower clearance and 5-fold greater systemic exposure than the S-enantiomer following oral administration of lansoprazole. Dexlansoprazole MR is a modified release formulation of dexlansoprazole, which employs a novel Dual Delayed Release (DDR) technology that delivers the drug in two discrete phases of release, thereby inhibiting newly activated proton pumps that turn over following initial PPI inactivation of H+,K+-ATPase. Dexlansoprazole MR maintains plasma drug concentrations above the threshold level longer than lansoprazole at all doses, resulting in an optimized drug exposure-intragastric pH relationship. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H+K+-ATPase proton pump in the gastric parietal cell, inhibition of this cell membrane enzyme ultimately blocks the final step in acid production.

In Vivo

Animal model

Formulation & Dosage

References

Aliment Pharmacol Ther. 2009 May 1;29(9):928-37; Clin Ther. 2010 Aug;32(9):1578-96.

CAS NO:	138530-94-6
规格:	≥98%

包装	价格(元)
50mg	电议
100mg	电议
250mg	电议
500mg	电议
1g	电议
5g	电议